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Abstract.As part of an investigative nephrotoxicity study, kidney tissues from juvenile
rats orally administered dabrafenib at different age intervals between postnatal day
(PND) 7 to 35 were investigated byMALDI and LDI imagingmass spectrometry (IMS)
to determine the chemical composition of tubular deposits. In the youngest age group
(PND 7-13), MALDI IMS demonstrated that a dabrafenib carboxylic acid metabolite
was diffusely localized to the regions of tubular deposits (medulla and
corticomedullary junction); however, no dabrafenib-related material was detected
directly from the deposits. Rather, the LDI IMS analysis determined that the deposits
were composed primarily of calcium phosphate. Based on these data, the dabrafenib
associated nephrotoxicity, including the formation of tubular deposits, was deter-
mined to be age dependent. Furthermore, immature renal function was hypothesized to be responsible for the
susceptibility of the youngest pups.
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Introduction
A mechanistic understanding of nonclinical toxicologicalevents in drug development can be important in deter-
mining the human relevance and driving an effective risk
assessment strategy. In such cases, the ability to investigate
the molecular and cellular processes at the basis of the toxico-
logical and pathologic findings induced by candidate drugs is
critical in gaining the required mechanistic insight [1]. There
are many analytical challenges associated with toxicological
investigations aimed at examining the relationship between
pathogenesis and the tissue distribution of a drug and its
metabolites. In this application, LC-MS analysis of tissue ho-
mogenate extracts can be of limited value because the spatial
information of analytes is lost. In some instances, tissue ho-
mogenate concentrations can be misleading. For example, if an
analyte within the tissue is highly localized, the homogeniza-
tion process will serve as a dilution and one may ignore a
possible pathologic association because the measured tissue
homogenate concentration is relatively low. Conversely, if an
analyte is determined to have a high tissue homogenate con-
centration, one may be incorrectly drawn to make an associa-
tion with tissue pathology.
Matrix-assisted laser desorption/ionization (MALDI)
imaging mass spectrometry (IMS) has emerged as a
powerful analytical tool for conducting mechanistic in-
vestigations into the tissue distribution of drugs and their
metabolites [2–4]. In MALDI IMS, mass spectra are
acquired across the surface of a tissue section creating
a dataset from which a two-dimensional ion intensity
image of any of the detected molecular species can be
generated. The power of IMS lies in the ability to
directly overlay the molecular information from the mass
spectrometric analysis with the underlying tissue section
to allow correlative visual comparisons of molecular and
histologic information. The successful utilization of IMS
in investigative toxicology studies is dependent on a
carefully crafted and executed study design.
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Dabrafenib (DAB), synonymous with TAFINLAR and
GSK2118436, is an ATP-competitive inhibitor of RAF kinase
activity. RAF kinases are a family of serine/threonine specific
protein kinases involved in the mitogen-activated protein ki-
nase (MAPK) pathway, which is a signaling cascade that
mediates cell proliferation, differentiation, and survival [5].
Genetic mutations in various components of the MAPK path-
way have been implicated in the progression of many human
cancers, including melanoma, where BRAFmutation is present
in around 50% of malignant tumors [6]. Dabrafenib has been
approved in adults for the treatment of BRAF V600E mutation
positive tumors as monotherapy and combination therapy with
trametinib, an allosteric noncompetitive inhibitor of mitogen-
activated protein kinases 1 and 2 (MEK1/MEK2).
In support of dabrafenib pediatric development, several
clinical and nonclinical studies were conducted, including tox-
icity studies in the juvenile rat. In the definitive juvenile rat
toxicity study, DAB-induced effects on the developing kidney
were observed (Laffan et al., manuscript in preparation). No
adverse kidney effects have been observed in adult animal
studies with dabrafenib. Renal microscopic findings in the
juvenile rats included tubular deposits, increased incidence of
cortical cysts, tubular dilation, and increased incidence of tu-
bular basophilia. Renal toxicity occurred with greater incidence
and severity in younger pups, when dosing was initiated during
the preweaning stage [before postnatal day (PND) 21], com-
pared with older pups, where dosing was initiated postweaning
(PND 22 or later). The tubular deposits were considered to be
responsible for the pathogenesis of the additional renal findings
in the proximal segments of the kidney due to the effects of
obstructive nephropathy. The formation of renal deposits in the
juvenile kidneywas not anticipated and the mechanismwas not
well understood; the potential for these tubular deposits to be
derived directly from DAB and/or its metabolites could not be
ruled out.
Themolecular composition of renal calculi can be indicative
of the pathogenesis leading to their formation [7]. Xenobiotics
have been shown to be responsible for the formation of kidney
deposits, either directly through precipitation or by disruptions
to kidney homeostasis (e.g., pH changes) that lead to the
precipitation of endogenous components [8, 9]. Further-
more, the differentiation of nephrotoxicity by develop-
mental stage suggests that the ontogeny associated with
xenobiotic elimination routes may play a role in the
formation of tubular deposits.
In this report, we present results from an additional study
conducted to further examine the potential age sensitivity to
dabrafenib induced renal toxicity initially observed in the de-
finitive juvenile rat study. This investigative study com-
bined multiple analytical approaches, including histopath-
ologic assessment, specialized clinical chemistry, and
urinalysis, in addition to mass spectrometric-based anal-
yses. Here, we highlight the results of the IMS experi-
ments used to analyze the kidney tissue distribution of
DAB and its metabolites and determine the molecular
composition of the renal deposits.
Experimental
Materials and Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise stated. 2,5-Dihydroxybenzoic
acid (DHB, purity 98%) was purchased from Sigma Aldrich
and purified by recrystallization prior to use. Calcium phos-
phate, dibasic (purity >98.5%) was purchased from Sigma-
Aldrich and calcium oxalate (purity>99.999%) was purchased
from Alfa Aesar (Ward Hill, MA, USA). Indium tin oxide
(ITO) coated glassmicroscope slideswas purchased fromBruker
(Billerica, MA, USA). Dabrafenib (DAB, GSK2118436A;
N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-
thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide)
from batch number JW211647-166P, 99.4% purity (% area) was
supplied by GlaxoSmithKline and was stable when stored refrig-
erated (5°C) and protected from light for the duration of the
study. Suspensions at concentrations of 2 and 10 mg/mL in
0.5% hydroxypropyl-methylcellulose (K15M) with 0.1% Tween
80 were dispensed weekly and were stable when stored refriger-
ated (5°C) for at least 15 d and protected from light.
Study Design
All animal procedures were conducted in an American Asso-
ciation for the Accreditation of Laboratory Animal Care
(AALAC)-accredited facility at GlaxoSmithKline (GSK) in
accordance with GSK policies on the care, welfare, and treat-
ment of laboratory animals, and they were reviewed and ap-
proved by GSK’s Institutional Animal Care and Use Commit-
tee (IACUC) as appropriate. Twenty-four time-mated female
Crl:CD-1 (ICR)BR rats were obtained for this study from
Charles River Laboratories Inc., (Raleigh, NC, USA). Mated
females or parturient females and their litters were housed
individually in plastic boxes containing Alpha-dri bedding
(Shepherd Specialty Papers, Inc., Kalamazoo, MI, USA), ex-
cept during the period of urine collection, when they were
housed individually in stainless steel cages. Throughout the
study, all animals were housed in a controlled environment
(64°F to 79°F; 30% to 70% relative humidity) with an approx-
imate 12-hour light/12-hour dark cycle. Litters were culled to
10 males/sex/litter on PND 4, weaned on PND 21, and then
group housed for the remainder of the study. Since the renal
findings occurred at a similar incidence in the males and
females in the definitive study, only males were evaluated in
this study. To accommodate the two dose levels with five
different treatment intervals and to control for maternal care,
five litters each (10/males per litter) were assigned to either the
vehicle or the test-article group; then, two pups each from five
litters were arbitrarily assigned different treatment periods to
comprise the 10 groups.
Treatment periods were from PND 7 to 13, PND 14 to 21,
PND 22 to 27, PND 28 to 35, or PND 7 to 35 (Table 1). Each
group consisted of N=10 juvenile male rats administered either
vehicle control (Groups 1–5) or 10/20 mg/kg/d DAB (Groups
6–10) by oral gavage. The dose level was 10 mg/kg/day from
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PND 7 to PND 21, and then increased to 20 mg/kg/d from PND
22 to PND 35 to recapitulate the definitive juvenile toxicity
study (Laffan et al., manuscript in preparation) in which the dose
was increased as the pups aged to maintain consistent systemic
exposure. For simplicity, individual juvenile rats are identified
throughout the text by their group number (G1–10) and a unique
rat number (R1–10) (e.g., G6R1). The PND x–x format is used
as shorthand for the various DAB dosing time frames.
Termination occurred 1 d after the treatment period ended
for each dose group (i.e., approximately 24 h after the last
dose). At necropsy, the right kidney was fixed by immersion
in 10% neutral buffered formalin and processed for light mi-
croscopic examination. The left kidney was bisected trans-
versely at the hilus, placed in a plastic cryogenic mold (both
cut surfaces side down), wrapped in foil and snap frozen in
liquid nitrogen, and stored in a freezer set to maintain –70°C
until all study samples were collected and shipped on dry ice
for MALDI IMS analysis. Upon receipt, prior to sectioning, all
tissues were maintained at –80°C.
Tissue Sectioning
Thin sections (6 μm) from the midline of the kidney tissues
were collected in a cryostat (–20°C) and mounted onto ITO
coated glass microscope slides. Sections serial to those collect-
ed for IMS were taken for hematoxylin and eosin (H&E)
staining to enable correlated histologic analysis. Prior to matrix
application, all tissue sections collected for IMS and all H&E
stained sections were scanned at high magnification (20x –
40x) using an Aperio Scanscope CS (Leica, Buffalo Grove,
IL, USA).
Matrix Application
For the MALDI IMS experiments, DHB was applied using
either a custom built sublimation apparatus or TM Sprayer
(HTX Technologies, Carrboro, NC, USA). For the MALDI
IMS experiments investigating the distribution of DAB and its
metabolites (data shown in Figures 2 and Figure 3), DHB
(50 mg/mL) in water/methanol (1:1 v/v) was applied using a
TMSprayer (HTX Technologies) with the following parameter
settings: number of passes=8; flow rate=0.1 mL/min; spray
temperature=70°C; velocity=1333 mm/min; track spacing=
3.0 mm; track offset=1.5 mm. For sublimation (data shown in
Figure 4), the system was operated under vacuum (~300 mTorr)
and a heating mantle was used to heat the chamber contain-
ing DHB to ~130°C for approximately 15 min. Based on
weight, approximately 12 mg of DHB was applied to the
slides. Following sublimation, slides were incubated in a
chamber saturated with methanol for approximately 20 min.
No additional preparation or processing was conducted on the
tissue sections analyzed by laser desorption ionization (LDI).
Imaging Mass Spectrometry (IMS)
Two separate methods of ionization were used to acquire the
IMS datasets: laser desorption ionization (LDI) and matrix-
assisted laser desorption/ionization (MALDI).
All MALDI and LDI IMS experiments were conducted
using a Bruker Solarix 7T Fourier transform-ion cyclotron
resonance mass spectrometer (FT-ICR MS). Images were ac-
quired at spatial resolutions ranging from 10 to 100 μm. Mass
spectra were acquired both in full scan mode (m/z 80–1000)
and continuous accumulation of selected ions (CASI) mode
where a narrow mass range (m/z 460–620) was selected to
enhance sensitivity for DAB-related material. LDI IMS exper-
iments were conducted by increasing the laser power setting
~2×–3× higher than the laser power settings typically used for
MALDI MS acquisition of DHB. All ion images were gener-
ated using FlexImaging v4.0 software from the raw data.
Unless specified otherwise, all ion images are displayed with
a mass tolerance of +/– 0.0005 Da, minimum intensity thresh-
old of 2%, and a maximum intensity threshold of 70%. Ion
images exported from FlexImaging were processed to remove
the black background and overlayed with the corresponding
H&E images using Photoshop CC (Adobe, San Jose, CA,
USA).
When analyzed by MALDI MS, DAB, carboxy-dabrafenib
(CDAB), hydroxy-dabrafinib (HDAB), and desmethyl-
dabrafenib (DDAB) exhibit peaks corresponding to a double
bond reduction or ring opening hydrogenation [M+H+2H]+ in
addition to the [M+H]+ peak (Electronic Supplementary Ma-
terial, Figure S2).
Additionally, when analyzed by MALDI MS, extensive
conversion (up to 90%) of CDAB to DDAB occurs through
decarboxylation (Electronic Supplementary Material,
Figure S3). The LC-MS quantification showed that CDAB
Table 1. Summary of Study Design and Dosing Regimen
Group number Treatment Treatment period (PND) Day of necropsy (PND) Dose level (mg/kg/d)
1 Vehicle PND 7–13 PND 14 0
2 Vehicle PND 14–21 PND 22 0
3 Vehicle PND 22–27 PND 28 0
4 Vehicle PND 28–35 PND 36 0
5 Vehicle PND 7–35 PND 36 0
6 DAB PND 7–13 PND 14 10
7 DAB PND 14–21 PND 22 10
8 DAB PND 22–27 PND 28 20
9 DAB PND 28–35 PND 36 20
10 DAB PND 7–35 PND 36 10/20
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was the predominant species in the kidney of the PND 7–14
rats and the concentration of native DDAB was negligible.
Given that the conversion of CDAB to DDAB was shown to
be consistent across a large range of concentrations the signal
for DDAB is used as a surrogate for CDAB and referred to
CDAB* throughout the text.
Results and Discussion
Light Microscopic Histopathologic Evaluation
Increased kidney weights and microscopic renal findings were of
highest incidence and severity in pups treated during preweaning
[Group 6 (PND 7 to 13) and Group 7 (PND 14 to 21)] compared
with pups that initiated treatment postweaning [Group 8 (PND 22
to 27) and Group 9 (PND 28 to 35)]. Pups treated continuously
from PND 7 to 35 (Group 10) presented most of the effects noted
during the preweaning period but findings, in total, were generally
less severe. Notably, the tubular deposits were present at high
incidence in pups treated anytime during preweaning in all three
groups; PND 7 to 13, 14, to 21 and 7 to 35. Importantly, no
tubular deposits were found in the groups dosed postweaning only
(PND22 to 27 and PND28 to 35). A similar incidence of deposits
were noted in pups treated continuously from PND 7 to 35,
suggesting those deposits present prior to PND 22 persisted
throughout the dosing period but did not increase with extended
duration of dosing beyond weaning.
The tubular deposits, primarily located in the medulla, were
characterized by clear to deeply basophilic crystalline to min-
eralized material filling the lumina. Optical images (unstained)
of representative kidney tissue sections from three juvenile rats
are presented in Figure 1a showing the high density of tubular
deposits observed in a PND 7–14 animal G6-R4 (left) in
comparison to a PND 7–35 animal G10-R2 (middle), where
markedly fewer deposits are still visible. No deposits were
observed in the kidney tissues from the control animal G1-R1
(right). The deposits ranged in size from 10 to 100 μm, as
shown in Figure 1b and c, which display magnified views of a
selected region of the kidney (G6-R4).
Other DAB-related microscopic renal findings included
minimal to moderate dilation of cortical and medullary tubules,
increased incidence of cortical cysts, minimal to mild degener-
ation (especially cytoplasmic basophilia) of cortical and med-
ullary tubules. These tubular deposits also resulted in the path-
ogenesis of secondary changes in more proximal segments of
kidneys, leading to obstructive nephropathy.
Figure 1. (a) Optical scan (unstained) of kidney tissue sections
from juvenile rats: G6-R4 (DAB10mg/kg/d; PND7–14), G10-R2
(DAB 10/20 mg/kg/d; PND 7–35), and G1-R1 (vehicle/PND 7–
14), (b) 5× and (c) 20× magnification views from juvenile rat G6-





















































Scheme 1. The primary metabolic pathway of DAB in humans
and preclinical species
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Figure 2. Optical scans of kidney tissue sections from PND 7–13 juvenile rats (a) G6-R2 and (b) G6-R3 analyzed by MALDI IMS in
CASImode (m/z 460–620) at 100 μmspatial resolution. (c) and (d) Respective ion images for CDAB* [M + 2H +H]+ (m/z 508.1083) and
quantity (ng/g of tissue) predicted using tissue mimetic model. (e) Pre-analysis optical scan of tissue mimetic model cores with
spiked concentration of CDAB labeled for each (f) ion image for CDAB* [M + 2H + H]+ (m/z 508.1083) from tissue model analyzed
under same conditions as the kidney tissue sections
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Renal Distribution of DAB and Metabolites
The primary metabolic pathway of DAB in humans and pre-
clinical species involves an oxidation cascade starting with the
tert-buty group (Scheme 1) [10]. Initial cytochrome P450
mediated oxidation results in the formation of HDAB followed
by further oxidation to form CDAB. A non-enzymatic decar-
boxylation mechanism has been proposed for the formation of
DDAB.
An LC-MS kidney tissue homogenate survey to character-
ize DAB and its metabolites was conducted on a representative
subset of animals from each dose group (Electronic Supple-
mentary Material, Figure S4). These data showed that the
highest concentration of DAB-related material was present in
the kidney tissues from the youngest rats [Group 6 ( PND 7–
13)] with the predominant DAB-related species detected in this
group (n=4) being CDAB (mean: 8190 [6114–11,657] ng/g)
followed by HDAB (mean: 442 [352–596] ng/g) and DDAB
(mean: 72 [38–110 ng/g). DABwas not detected in the PND 7–
13 samples by LC-MS. In the kidney tissues from the addition-
al dosing groups, which were all assessed on PND 22 or older,
DAB was not detected and markedly lower levels of DAB-
related metabolites were present relative to the PND 7–13
group. The LC-MS data provides a temporal link between the
quantity of DAB-related material (mainly CDAB) and the
observed kidney injury in younger juvenile rats. However,
these data provide no insight into the relationship between
DAB or its metabolites and the tubular deposits, which were
believed to be the primary source of injury.
Our initial MALDI IMS experiments were focused on de-
termining the distribution of DAB and its metabolites in the
kidney given the literature precedence for drug or drug metab-
olite precipitation as the cause of tubular deposits [8, 9, 11].
Figure 2 displays the distribution of CDAB* in kidney tissue
sections from two PND 7–13 juvenile rats (G6-R2 and G6-R3).
In both animals, CDAB* was diffusely localized predominant-
ly to the inner medulla and pelvic regions with less intense
signals from the outer medulla and cortex (Figure 2c and d). An
estimate of the tissue concentration of CDAB* in these section
was generated using a tissue mimetic model (Figure 2e and f).
As previously described [12], the tissue mimetic model can be
used to estimate drug quantities by comparing the average ion
signal detected by MALDI IMS for an analyte in a tissue
section to a calibration curve analyzed in parallel. For G6-R2,
the concentration of CDAB was estimated to be 8000 ng/g by
the MALDI IMS tissue model approach compared with
11,600 ng/g by LC-MS and for G6-R3, 6400 ng/g by MALDI
IMS comparedwith 6100 ng/g by LC-MS. Considering that the
Figure 3. (a) Optical scan of kidney tissue sections from PND 7–13 juvenile rat G6-R2 analyzed by MALDI IMS in CASI mode (m/z
460–620) at 25 μm spatial resolution. (b) Ion image for CDAB* [M + 2H + H]+ (m/z 508.1083). (c) Serial H&E. (d) 10× magnification of
outlined region in optical scan. (e) Magnified view of CDAB* ion image co-registered with optical scan. (f) Magnified view of CDAB*
ion image co-registered with H&E. (g) Histopathology annotated H&E
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MALDI IMS results are generated on a single tissue section
(<1 mg) compared with the LC-MS results, which are gener-
ated on extracts from half of a kidney (>200 mg), these results
are in relatively good agreement, and differences in the esti-
mated quantities might be, at least partially, attributed to re-
gional concentration differences in the kidney.
The low spatial resolution (100 μm) imaging experiments
displayed in Figure 2 helped correlate the distribution of DAB-
related material to the gross anatomical features of the kidney
sections with high sensitivity. In addition to these, several high
spatial resolution imaging experiments were conducted to pro-
vide a more detailed view of the relationship between the
CDAB* and the tissue histology and rule out a direct associa-
tion with the tubular deposits. For example, Figure 3 displays
the distribution of CDAB* at 25 μm spatial resolution in a
kidney tissue section from a PND 7–13 juvenile rat (G6-R2).
The focally intense regions throughout the medulla where
CDAB* is detected with highest intensity (Figure 3b) corre-
spond to dilated and degenerate collecting ducts in the serial
H&E (Figure 3c). This is more clearly illustrated in the mag-
nified views (Figure 3d–g) showing the overlays of the ion
image for CDAB* with the optical scan and H&E. Here, the
distribution of CDAB* is shown to be highly localized to the
lumen of the damaged collecting ducts. Importantly, neither
CDAB* nor any other DAB-related material was detected
directly from the tubular deposits in any of the imaging exper-
iments conducted.
Low intensity levels of HDAB were detected in the
cortical regions of the PND14 assessed kidney tissues (data
not shown); however, neither DAB nor any additional
DAB-metabolites were observed. No DAB-related material
was detected by MALDI IMS or LC-MS in kidney tissues
from the PND 7–35 group despite the presence of tubular
deposits.
Renal Deposit Characterization
Determining the composition of the deposits was important for
insight into the mechanism of DAB-related nephrotoxicity in
the preweaning rats. The MALDI IMS experiments revealed
numerous peaks detected exclusively from the tubular deposits.
Based on accurate mass and isotopic distribution, the deposit-
specific peaks were identified as various DHB-calcium clus-
ters. For example, Figure 4 displays ion images for several of
Figure 4. (a) Optical scan of kidney tissue sections from PND 7–13 juvenile rat G6-R4 analyzed byMALDI IMS in fullscanmode (m/z
100–1000) at 10 μm spatial resolution. (b) Ion image for [3DHB – H + Ca]+ (m/z 501.0339) in green, and glycerophosphocholine [M +
K]+ (m/z 296.0659) in red. (c) Ion image for [2DHB – 2H + Ca]•+ (m/z 345.9999). (d) Ion image for [2DHB –O – 2H + Ca]•+ (m/z 330.0047)
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these high intensity matrix-calcium clusters that were detected
exclusively from the deposits in a section from PND 7–13
animal G6-R2. A similar pattern of cluster formation was
reported by Dubois et al.[13], where it was shown that DHB
readily forms clusters in the presence of high concentrations of
calcium. This was useful information, although not surprising,
as calcium salts, including calcium oxalate and calicum
phosphate, are known to be present in approximately 80% of
renal calculi (i.e., calcium based deposits) [14]. However,
distinguishing between calcium oxalate and calcium phosphate
deposits can be important because their formation is driven by
different pathogenic mechanisms [14–16].
Further characterization of the deposits was conducted
using LDI IMS, where regions of the kidney tissues were
analyzed in the absence of a MALDI matrix. From these
experiments, it was possible to detect a wide variety of calcium
phosphate species directly from the tubular deposits. For ex-
ample, targeted regions of a kidney tissue section from a PND
7–13 juvenile rat G6-R2 were analyzed by LDI IMS and are
shown in Figure 5a and b. The spectra generated from the
deposits contained a large number of peaks (Figure 5c), which,
based on accurate mass and isotope pattern, were primarily
identified as various hydrated calcium phosphate species
(Figure 5d). Figure 5e and f display the ion images for two of
these calcium phosphate species: m/z 272.8549 (Ca2H3P2O8)
in red and m/z 228.91757 (Ca2H6PO7) in green. Interestingly,
these two species are detected with different distributions from
within the deposits, where m/z 228.91757 is localized to the
Figure 5. (a) Optical scan of a region of a kidney tissue section from PND 7–13 juvenile rat G6-R2 analyzed by LDI IMS without
matrix at 10 μm spatial resolution. (b) Serial H&E. (c) Partial view of the spectrum generated by averaging all spectra from pixels
localized to the deposits. (d) Peak identification table for the most abundant peaks (labeled) in the mass spectrum. (e) Overlayed ion
images for m/z 272.8550 (Ca2H3P2O8) in red, and m/z 228.9097 (Ca2H6PO7) green. (f) Magnified view (20×)
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perimeter and m/z 272.8549 to the inner area. It is known that
the composition of renal calculi can consist of heterogeneous
layers attributable to the processes of nucleation, crystal
growth, and aggregation [17].
In order to verify the proposed peak assignments from the
tubular deposits, tissue section profiles were compared with
standards of calcium oxalate and calcium phosphate byMALDI
and LDI MS (Figure 6). A peak list table is shown in Table 2
Figure 6. Saturated soluions of calcium phosphate and calcium oxalate in water were precipitated onto an ITO coated glass slide
by pipetting 1 μL (×3). For MALDI MS, DHBmatrix was applied to the kidney tissue section using a TMSprayer and to the standards
by pipetting 1 μL [50mg/mL H2O/MeOH (1:1 v/v)]. Nomatrix was applied for the LDI mass spectra. BothMALDI and LDI fullscan (m/z
100–1000) mass spectra were manually acquired in positive ion mode. MALDI mass spectra generated by averaging 50 scans (50
laser shots each) from (a) tubular deposit in a kidney tissue section from PND 7–13 juvenile rat G6-R2. (c) Calcium phosphate
standard and (e) calcium oxalate standard. LDI mass spectra generated by averaging 100 scans (500 laser shots each) from (b)
tubular deposit in a juvenile kidney tissue section (G6-R2), (d) calcium phosphate, and (f) calcium oxalate
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as a reference for the highest intensity ions detected in each
spectrum. Figure 6a, c, and e display representative MALDI
mass spectra generated from the kidney deposits (G6-R2), the
calcium phosphate standard, and the calcium oxalate standard,
respectively. The MALDI mass spectra generated for these
three samples are very similar, where the major species detected
are DHB-calcium adducts. In contrast, the LDI mass spectra
(Figure 6b, e, and f) provide a clear distinction, where the
spectra from the renal deposits and calcium phosphate stan-
dard show a similar distribution of calcium phosphate spe-
cies. Calcium hydroxide clusters are the predominant species
in LDI mass spectrum generated from the calcium oxalate
standard.
These experiments led us to the conclusion that the tubular
deposits were primarily composed of calcium phosphate and
were devoid of DAB-related material. Additionally, the molec-
ular composition of the deposits as detected by MALDI and
LDI MS was consistent between the PND 7–14 and PND 7–35
treatment groups (data not shown). The differences in the LDI
mass spectra from the imaging experiment (Figure 5c) and the
profiling experiment (Figure 6a) are likely due to the higher
laser energy (less attenuation) used for acquistion of the data in
Figure 5 relative to the data in Figure 6. This was consistently
observed in the LDI MS experiments, where differences in
laser energy affected the intensity distribution of the various
calcium phosphate clusters detected, but not the overall com-
position of the spectra. The putative molecular species listed in
Table 2 were generated using a logical combination of the
elements in the predicted ion formula; an exhaustive structural
characterization of the species detected, beyond the LDI and
MALDI MS, was not conducted.
Mechanistic Hypothesis for Nephrotoxicity
Determining the precise etiology of DAB juvenile nephrotox-
icity was beyond the scope of this study design; however, some
mechanistic insights for risk assessment can be gained from
these data. Based on the histopathologic assessment alone,
juvenile rats administered DAB exhibit an age-dependent
nephrotoxic response. Specifically, the incidence and severity
of nephrotoxicity was greatest in rats where DAB administra-
tion was initiated in younger rat pups during the preweaning
phase. For older pups that began receiving DAB postweaning,
there were fewer and less severe kidney findings. These obser-
vations suggest a unique sensitivity of the developing kidney to
the nephrotoxic potential of DAB in rats.
The LC-MS analysis showed markedly higher quantites of
CDAB in the kidneys of the youngest rats (PND 7–13) relative
to the older dosing groups. A similar pattern was observed in a
previous juvenile rat toxicokinetic study with the same dosing
regimen, where CDAB was the predominant circulating me-
tabolite with 3 to 5 times higher dose-dependent plasma expo-
sure during the preweaning period compared with postweaning
(Laffan et al, manuscript in preparation).
Several factors may have contributed to the increased
renal tissue concentration of DAB-related material in the
youngest pups (PND 7–13). The process of bile forma-
tion in rats (and humans) is known to be immature at
birth and therefore biliary elimination of many drugs is
impaired during the neonatal period [18–21]. The biliary
clearance system gradually develops over the first several
postnatal weeks to adult levels. Given that fecal elimina-
tion (which includes biliary) is the major clearance route
for DAB and its metabolites in adult rats [10], the
increased systemic and kidney concentrations in the
youngest pups may be reflective of undeveloped biliary
excretion.
In the preweaning rats administered DAB, the primary
site of toxicologic injury was the tubular epithelial cells
in the distal nephron (collecting duct) and the formation
of tubular deposits in the inner medulla. The formation
of drug-induced kidney deposits can either be a direct
result of drug or metabolite precipitation or the drug or
metabolites may cause physiological perturbations (e.g.,
changes in pH) that lead to the precipitation of endoge-
nous components [11]. The MALDI and LDI IMS anal-
yses support that the tubular deposits consisted primarily
of calcium phosphate and did not contain any DAB-
related material. Because the distal nephron is recognized
to be a primary site of calcium homeostasis [22], it is
possible that damage to the tubular epithelium resulting
from DAB administration in the preweaning animals
(Groups 6 and 7) could trigger localized disruption of
the acid-base homeostasis resulting in formation of cal-
cium phosphate calculi. Furthermore, the preweaning rats
may be more susceptible to such an insult because of
immature renal function. Animal studies have demon-
strated an immaturity and decreased activity of several
transporters related to the maintenance of acid-base ho-
meostasis in the neonatal kidney [23]. Karashima et al.
[24] found that in rats, carbonic anhydrase II levels
increased from 14% to 40% of adult levels from the
first to third postnatal week. Renal phosphate transport
in rats also reaches maturity during the third postnatal
week [25].
The deposits observed in the PND 7–35 extended treatment
group are likely formed during the preweaning period (PND 7–
21) based on the observation that there was no increase in the
incidence and severity of the calculi formed when comparing
these animals to the PND 7–13 treatment group. Because
calculi are very slowly resorbed, once formed, tubular injury
will likely persist through or after PND 35, even though the
direct nephrotoxic effects of the compound appear to diminish
after PND 22.
Determining whether the initial tubular injury was
directly or indirectly caused by DAB or its metabolites
was beyond the scope of this investigation. Nonetheless,
given the markedly high levels of CDAB detected in the
kidneys of the PND 7–13 animals, the localization of
CDAB and deposits within the kidney, and the absence
of CDAB in the kidneys of unaffected older animals, a
direct link does seem plausible.
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Conclusions
Nonclinical studies in drug development are conducted to
assess safety in animal models and build a risk assessment for
patients. Toxicologists traditionally screen for adverse findings
by histologic examination of tissues with light or even electron
microscopy, in addition to monitoring for urine or plasma
biomarkers of pathology. Imaging MS provides a platform to
more directly link the chemistry and biology involved in the
processes associated with toxicologic effects; specifically,
overlaying the tissue distribution of drugs and their metabolites
with the location of changes in tissue morphology. The appli-
cation of both MALDI and LDI IMS in this study serves as an
example of how this platform can impact drug discovery and
development. IMS analysis of juvenile rat kidney tissues was
able to add a deeper mechanistic understanding to the nephro-
toxicity than LC-MS homogenate data alone, by characterizing
the tissue distribution of the DAB metabolites and determining
the chemical composition of the tubular deposits. From these
data, along with histologic findings, a more complete risk
assessment for pediatric treatment with dabrafenib is possible.
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